Document is current
Any future updates will be listed below
-
Authors
Hanson, Jesse E. https://orcid.org/0000-0003-3059-5132
Yuan, Hongjie https://orcid.org/0000-0002-8127-7145
Perszyk, Riley E.
Banke, Tue G.
Xing, Hao
Tsai, Ming-Chi
Menniti, Frank S. https://orcid.org/0000-0003-2612-9534
Traynelis, Stephen F. https://orcid.org/0000-0002-3750-9615
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS111619)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD082373)
- License Information
-
More Information
Article History
Received: 9 March 2023
Revised: 24 April 2023
Accepted: 15 May 2023
First Online: 27 June 2023
Competing interests
: Frank S. Menniti was involved in the development of CP-101,606, MIJ-821, and CAD-9303 and is inventor on patents related to these compounds, was founder of Mnemosyne Pharmaceuticals, Inc., and is founder of MindImmune Therapeutics, Inc. Hongjie Yuan is PI on a research grant from Sage Therapeutics to Emory University School of Medicine. Tue G. Banke is PI on research grants from Neumora and Neurocrine to Emory University School of Medicine. Hao Xing has nothing to disclose. Riley E. Perszyk has nothing to disclose. Jesse E. Hanson and Ming-Chi Tsai are employees of Genentech. Stephen F. Traynelis is a member of the SAB for Eumentis Therapeutics, Sage Therapeutics, and Combined Brain, is a member of the Medical Advisory Board for the GRIN2B Foundation and the CureGRIN Foundation, is an advisor to GRIN Therapeutics and Neurocrine, is co-founder of NeurOp Inc. and AgriThera Inc., and is a member of the Board of Directors of NeurOp Inc.
